Physician profile
Paul Quesada
NPI 1912994559
$315.68
in general payments reported to CMS, 2019-2025
10 companies · $30.50 in 2025
The $30.50 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.33 · 2020: $14.63 · 2023: $31.24 · 2024: $148 · 2025: $30.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $209.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $79.09 | 2019-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Sanofi Pasteur INC. | $59.57 | 2019-2023 | |
| Alk-Abello, INC | $39.72 | 2024 | Ragwitek, Odactra, Grastek |
| Cranial Technologies, INC | $31.34 | 2023-2024 | Doc Band |
| Glaxosmithkline, LLC. | $22.82 | 2024 | Shingrix, Bexsero, Arexvy |
| Ironshore Pharmaceuticals INC. | $21.06 | 2019 | |
| Verrica Pharmaceuticals INC. | $18.56 | 2024 | Ycanth |
| Phadia US INC. | $16.44 | 2025 | Immunocap |
| Pfizer INC. | $14.99 | 2024 | |
| Genentech USA, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Quesada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.